A hallucinogen is a psychoactive agent which most likely causes hallucinations, perceptual anomalies, and other substantial subjective changes in thoughts, emotion, and consciousness. The common types of hallucinogens are psychedelics, dissociatives and deliriants. Although hallucinations are a common symptom of amphetamine psychosis,
amphetamines are not considered hallucinogens as they are not a primary
effect of the drugs themselves. While hallucinations can occur when
abusing stimulants, the nature of stimulant psychosis is not unlike
delirium.
Nomenclature
A
debate persists on criteria which would easily differentiate a
substance which is 'psychedelic' from one 'hallucinogenic'. Sir Thomas
Browne in 1646 coined the term 'hallucination' from the Latin word "alucinari" meaning "to wander in the mind".
A 'hallucinogen' and a 'psychedelic' may refer correctly to the
same substance. Psychedelics are considered by many to be the
'traditional' or 'classical hallucinogens'. A 'hallucinogen' in this
sense broadly refers to any substance which causes changes in perception
or hallucinations, while psychedelics also carry a connotation of psychedelic culture.
Psychedelics (classical hallucinogens)
The word psychedelic (From Ancient Greek ψυχή (psychê) mind, soul + δηλος (dêlos) manifest, reveal
+ -ic) was coined to express the idea of a drug that makes manifest a
hidden but real aspect of the mind. It is commonly applied to any drug
with perception-altering effects such as LSD and other ergotamine derivatives, DMT and other tryptamines including the alkaloids of Psilocybe spp., mescaline and other phenethylamines.
The classical hallucinogens are considered to be the
representative psychedelics and LSD is generally considered the
prototypical psychedelic.
In order to refer to the LSD-like psychedelics, scientific authors have
used the term "classical hallucinogen" in the sense defined by Glennon
(1999): "The classical hallucinogens are agents that meet Hollister's
original definition, but are also agents that: (a) bind at 5-HT2
serotonin receptors, and (b) are recognized by animals trained to
discriminate 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) from
vehicle.
Otherwise, when the term 'psychedelic' is used to refer only to the
LSD-like psychedelics (a.k.a. the classical hallucinogens), authors
explicitly point that they intend 'psychedelic' to be understood
according to this more restrictive interpretation (e.g. see Nichols,
2004).
One explanatory model for the experiences provoked by psychedelics is the "reducing valve" concept, first articulated in Aldous Huxley's book The Doors of Perception.
In this view, the drugs disable the brain's "filtering" ability to
selectively prevent certain perceptions, emotions, memories and thoughts
from ever reaching the conscious mind. This effect has been described
as mind expanding, or consciousness expanding, for the drug "expands" the realm of experience available to conscious awareness.
While possessing a unique mechanism of action, cannabis or marijuana has historically been regarded alongside the classic psychedelics.
Research chemicals and designer drugs
A designer drug is a structural or functional analog of a controlled
substance that has been designed to mimic the pharmacological effects of
the original drug while at the same time avoid being classified as
illegal (by specification as a research chemical) and/or avoid detection in standard drug tests. Many designer drugs and research chemicals are hallucinogenic in nature, such as those in the 2C and 25-NB (NBOMe) families.
Dissociatives
Dissociatives produce analgesia, amnesia and catalepsy at anesthetic doses.
They also produce a sense of detachment from the surrounding
environment, hence "the state has been designated as dissociative
anesthesia since the patient truly seems disassociated from his
environment."
Dissociative symptoms include the disruption or compartmentalization of
"...the usually integrated functions of consciousness, memory, identity
or perception." Dissociation of sensory input can cause derealization, the perception of the outside world as being dream-like, vague or unreal. Other dissociative experiences include depersonalization,
which includes feeling dissociated from one's personality; feeling
unreal; feeling able to observe one's actions but not actively take
control; being unable to associate with one's self in the mirror while
maintaining rational awareness that the image in the mirror is the same
person.
Simeon (2004) offered "...common descriptions of depersonalisation
experiences: watching oneself from a distance (similar to watching a
movie); candid out-of-body experiences; a sense of just going through the motions; one part of the self acting/participating while the other part is observing;...."
The classical dissociatives achieve their effect through blocking the signals received by the NMDA receptor set (NMDA receptor antagonism) and include ketamine, methoxetamine (MXE), phencyclidine (PCP), dextromethorphan (DXM), and nitrous oxide. However, dissociation is also remarkably administered by salvinorin A's (the active constituent in Salvia divinorum shown to the left) potent κ-opioid receptor agonism, though sometimes described as an atypical psychedelic.
Some dissociatives can have CNS depressant effects, thereby carrying similar risks as opioids,
which can slow breathing or heart rate to levels resulting in death
(when using very high doses). DXM in higher doses can increase heart
rate and blood pressure and still depress respiration. Inversely, PCP
can have more unpredictable effects and has often been classified as a
stimulant and a depressant in some texts along with being as a
dissociative. While many have reported that they "feel no pain" while
under the effects of PCP, DXM and Ketamine, this does not fall under the
usual classification of anesthetics in recreational doses (anesthetic
doses of DXM may be dangerous). Rather, true to their name, they process
pain as a kind of "far away" sensation; pain, although present, becomes
a disembodied experience and there is much less emotion associated with
it. As for probably the most common dissociative, nitrous oxide, the principal risk seems to be due to oxygen deprivation.
Injury from falling is also a danger, as nitrous oxide may cause sudden
loss of consciousness, an effect of oxygen deprivation. Because of the
high level of physical activity and relative imperviousness to pain
induced by PCP, some deaths have been reported due to the release of
myoglobin from ruptured muscle cells. High amounts of myoglobin can
induce renal shutdown.
Many users of dissociatives have been concerned about the
possibility of NMDA antagonist neurotoxicity (NAN). This concern is
partly due to William E. White, the author of the DXM FAQ, who claimed that dissociatives definitely cause brain damage. The argument was criticized on the basis of lack of evidence and White retracted his claim. White's claims and the ensuing criticism surrounded original research by John Olney.
In 1989, John Olney
discovered that neuronal vacuolation and other cytotoxic changes
("lesions") occurred in brains of rats administered NMDA antagonists,
including PCP and ketamine.
Repeated doses of NMDA antagonists led to cellular tolerance and hence
continuous exposure to NMDA antagonists did not lead to cumulative
neurotoxic effects. Antihistamines such as diphenhydramine, barbiturates
and even diazepam have been found to prevent NAN. LSD and DOB have also been found to prevent NAN.
Deliriants
Deliriants, as their name implies, induce a state of delirium
in the user, characterized by extreme confusion and an inability to
control one's actions. They are called deliriants because their
subjective effects are similar to the experiences of people with
delirious fevers. The term was introduced by David F. Duncan and Robert S. Gold to distinguish these drugs from psychedelics and dissociatives, such as LSD and ketamine respectively, due to their primary effect of causing delirium, as opposed to the more lucid states produced by the other hallucinogens.
Despite the fully legal status of several common deliriant plants, deliriants are largely unpopular as recreational drugs due to the severe, generally unpleasant and often dangerous nature of the hallucinations produced.
Typical or classical deliriants are those which block the muscarinic acetylcholine receptors (antagonism). These are said to be anticholinergic. Many of these compounds are produced naturally by plant genera belonging to the nightshade family Solanaceae, such as Datura, Brugmansia and Latua in the New World and Atropa, Hyoscyamus and Mandragora in the Old World. These tropane alkaloids are poisonous and can cause death due to tachycardia-induced heart failure and hyperthermia even in small doses. Additionally, over-the-counter antihistamines such as diphenhydramine (brand name Benadryl) and dimenhydrinate (brand name Dramamine) also have an anticholinergic effect.
Uncured tobacco is also a deliriant due to its intoxicatingly high levels of nicotine.
The fly agaric mushroom, Amanita muscaria, is often informally lumped with the nightshade plants as a deliriant, though regarded as a dissociative with some regularity as well. This may be explained by the familiarity of both A. muscaria and Atropa belladonna
to European culture, their formal statuses as deadly poisons, and their
generally undesirable, unpleasant, and dangerous nature, with the
potential for death from physical and behavioral toxicity a possibility
even when dosages are carefully considered.
Nutmeg has deliriant and hallucinogenic effects as well due to some of its psychoactive chemicals, such as myristicin, which may be anticholinergic like the tropane alkaloids of the nightshade plants, or as suggested by Alexander Shulgin, partially metabolized into the empathogen-entactogen MMDA.
History of use
Psychedelics,
dissociatives, and deliriants have a long history of use within
medicinal and religious traditions around the world including shamanic forms of ritual healing and divination, initiation rites, and rituals of syncretistic movements such as União do Vegetal, Santo Daime, and the Native American Church.
In the context of religious practice, psychedelic drug use, as well as other substances such as tobacco (hypnotic), are referred to as entheogens. In some places peyote is classified as 'sacrament' for part of religious ceremonies, and is legally condoned for such use.
Hallucinogenic substances are among the oldest drugs used by human kind, as hallucinogenic substances naturally occur in mushrooms, cacti and a variety of other plants.
Numerous cultures worldwide have endorsed the use of hallucinogens in
medicine, religion and recreation, to varying extents, while some
cultures have regulated or outright prohibited their use. In most
developed countries today, the possession of many hallucinogens, even
those found commonly in nature, is considered a crime punishable by fines, imprisonment or even death. In some countries, such as the United States and the Netherlands, partial deference may be granted to traditional religious use by members of indigenous ethnic minorities such as the Native American Church and the Santo Daime Church. Recently the União do Vegetal, a Christian-based religious sect whose composition is not primarily ethnicity-based, won a United States Supreme Court decision authorizing its use of ayahuasca. However, in Brazil, ayahuasca use in a religious context has been legal since 1987. In fact, it is a common belief among members of the União do Vegetal that ayahuasca presents no risk for adolescents within the church, as long as they take it within a religious context.
Traditional religious and shamanic use
Historically, hallucinogens have been commonly used in religious or shamanic rituals. In this context they are referred to as entheogens, and are used to facilitate healing, divination, communication with spirits, and coming-of-age ceremonies. Evidence exists for the use of entheogens in prehistoric times, as well as in numerous ancient cultures, including Ancient Egyptian, Mycenaean, Ancient Greek, Vedic, Maya, Inca and Aztec cultures. The Upper Amazon is home to the strongest extant entheogenic tradition; the Urarina of the Peruvian Amazon, for instance, continue to practice an elaborate system of ayahuasca shamanism, coupled with an animistic belief system.
Shamans consume hallucinogenic substances in order to induce a
trance. Once in this trance, shamans believe that they are able to
communicate with the spirit world, and can see what is causing their
patients' illness. The Aguaruna of Peru believe that many illnesses are
caused by the darts of sorcerers. Under the influence of yaji, a hallucinogenic drink, Aguaruna shamans try to discover and remove the darts from their patients.
Concerning lycanthropy
(werewolves) and the use of hallucinogenic drugs, Frida G. Surawicz and
Richard Banta wrote "In the first case, this was brought on by LSD and
strychnine and continued casual marijuana use... Concerning drugs as
causative agents, it is interesting to note that opium has been
mentioned in a dual capacity, namely as a drug which can cause
lycanthropy as well as a drug for its treatment."
Early scientific investigations
Although natural hallucinogenic drugs have been known to mankind for millennia, it was not until the early 20th century that they received extensive attention from Western science. Earlier beginnings include scientific studies of nitrous oxide
in the late 18th century, and initial studies of the constituents of
the peyote cactus in the late 19th century. Starting in 1927 with Kurt Beringer's Der Meskalinrausch
(The Mescaline Intoxication), more intensive effort began to be focused
on studies of psychoactive plants. Around the same time, Louis Lewin published his extensive survey of psychoactive plants, Phantastica (1928). Important developments in the years that followed included the re-discovery of Mexican psilocybin mushrooms (in 1936 by Robert J. Weitlaner) and Christmas vine (in 1939 by Richard Evans Schultes). Arguably the most important pre-World War II development was by Albert Hofmann's 1938 discovery of the semi-synthetic drug LSD, which was later discovered to produce hallucinogenic effects in 1943.
Hallucinogens after World War II
After World War II there was an explosion of interest in hallucinogenic drugs in psychiatry, owing mainly to the invention of LSD. Interest in the drugs tended to focus on either the potential for psychotherapeutic applications of the drugs (see psychedelic psychotherapy), or on the use of hallucinogens to produce a "controlled psychosis", in order to understand psychotic disorders such as schizophrenia.
By 1951, more than 100 articles on LSD had appeared in medical
journals, and by 1961, the number had increased to more than 1000
articles. Hallucinogens were also researched in several countries for their potential as agents of chemical warfare. Most famously, several incidents associated with the CIA's MK-ULTRA mind control research project have been the topic of media attention and lawsuits.
At the beginning of the 1950s, the existence of hallucinogenic drugs was virtually unknown to the general public in the West. However this soon changed as several influential figures were introduced to the hallucinogenic experience. Aldous Huxley's 1953 essay The Doors of Perception, describing his experiences with mescaline, and R. Gordon Wasson's 1957 Life magazine article (Seeking the Magic Mushroom) brought the topic into the public limelight. In the early 1960s, counterculture icons such as Jerry Garcia, Timothy Leary, Allen Ginsberg and Ken Kesey advocated the drugs for their psychedelic effects, and a large subculture
of psychedelic drug users was spawned. Psychedelic drugs played a major
role in catalyzing the vast social changes initiated in the 1960s. As a result of the growing popularity of LSD and disdain for the hippies with whom it was heavily associated, LSD was banned in the United States in 1967.
This greatly reduced the clinical research about LSD, although limited
experiments continued to take place, such as those conducted by Reese
Jones in San Francisco.
As early as the 1960s, research into the medicinal properties of
LSD was being conducted. It has been found that LSD is a fairly
effective treatment for mental disorders such as obsessive compulsive
disorder (OCD). "Savage et al. (1962) provided the earliest report of
efficacy for a hallucinogen in OCD, where after two doses of LSD, a
patient who suffered from depression and violent obsessive sexual
thoughts experienced dramatic and permanent improvement (Nichols 2004:
164)."
Starting in the mid-20th century, psychedelic drugs has been the
object of extensive attention in the Western world. They have been and
are being explored as potential therapeutic agents in treating depression, posttraumatic stress disorder, obsessive–compulsive disorder, alcoholism, drug addiction, cluster headaches,
and other ailments. Early military research focused on their use as
incapacitating agents. Intelligence agencies tested these drugs in the
hope that they would provide an effective means of interrogation, with little success.
Yet the most popular, and at the same time most stigmatized, use
of psychedelics in Western culture has been associated with the search
for direct religious experience, enhanced creativity, personal development, and "mind expansion". The use of psychedelic drugs was a major element of the 1960s counterculture, where it became associated with various social movements and a general atmosphere of rebellion and strife between generations.
Despite prohibition, the recreational, spiritual, and medical use of psychedelics continues today. Organizations, such as MAPS and the Heffter Research Institute, have arisen to foster research into their safety and efficacy, while advocacy groups such as the Center for Cognitive Liberty and Ethics
push for their legalization. In addition to this activity by
proponents, hallucinogens are also widely used in basic science research
to understand the mind and brain. However, ever since hallucinogenic
experimentation was discontinued in the late 1960s, research into the
therapeutic applications of such drugs have been almost nonexistent,
that is until this last decade where research has finally been allowed
to resume.
Legal status and attitudes
In
Canada, mescaline is listed as prohibited under schedule III of the
Controlled Drugs and Substances Acts, but peyote is specifically exempt
and legally available.
As of 2008, most well-known hallucinogens (aside from dextromethorphan, diphenhydramine and dimenhydrinate)
are illegal in most Western countries. In the United States
hallucinogens are classified as a schedule 1 drug. The 3-pronged test
for schedule 1 drugs is as follows: the drug has no currently accepted
medical use, there is a lack of safety for the use of the drug under
medical supervision, and the substance has a high potential for abuse. One notable exception to the current criminalization trend is in parts of Western Europe, especially in the Netherlands, where cannabis is considered to be a "soft drug".
Previously included were hallucinogenic mushrooms, but as of October
2007 the Netherlands officials have moved to ban their sale following
several widely publicized incidents involving tourists.
While the possession of soft drugs is technically illegal, the Dutch
government has decided that using law enforcement to combat their use is
largely a waste of resources. As a result, public "coffeeshops" in the
Netherlands openly sell cannabis for personal use, and "smart shops"
sell drugs like Salvia divinorum, and until the ban of psilocybin mushrooms took effect, they were still available for purchase in smartshops as well.
Despite being scheduled as a controlled substance in the mid-1980s, MDMA's popularity has been growing since that time in western Europe and in the United States.
Attitudes towards hallucinogens other than cannabis have been
slower to change. Several attempts to change the law on the grounds of freedom of religion have been made. Some of these have been successful, for example the Native American Church in the United States, and Santo Daime in Brazil.
Some people argue that a religious setting should not be necessary for
the legitimacy of hallucinogenic drug use, and for this reason also
criticize the euphemistic use of the term "entheogen". Non-religious
reasons for the use of hallucinogens including spiritual, introspective, psychotherapeutic, recreational and even hedonistic motives, each subject to some degree of social disapproval, have all been defended as the legitimate exercising of civil liberties and freedom of thought.
Several medical and scientific experts, including the late Albert Hofmann,
advocate the drugs should not be banned, but should be strongly
regulated and warn they can be dangerous without proper psychological
supervision.
Psychedelics and mental illnesses in long-term users
Most psychedelics are not known to have long-term physical toxicity. However, entactogens such as MDMA that release neurotransmitters may stimulate increased formation of free radicals possibly formed from neurotransmitters released from the synaptic vesicle. Free radicals are associated with cell damage in other contexts, and have been suggested to be involved in many types of mental conditions including Parkinson's disease, senility, schizophrenia, and Alzheimer's.
Research on this question has not reached a firm conclusion. The same
concerns do not apply to psychedelics that do not release
neurotransmitters, such as LSD, nor to dissociatives or deliriants.
No clear connection has been made between psychedelic drugs and organic brain damage. However, hallucinogen persisting perception disorder (HPPD) is a diagnosed condition wherein certain visual effects of drugs persist for a long time, sometimes permanently, although science and medicine have yet to determine what causes the condition.
A large epidemiological study in the U.S. found that other than
personality disorders and other substance use disorders, lifetime
hallucinogen use was not associated with other mental disorders, and
that risk of developing a hallucinogen use disorder was very low.
How hallucinogens affect the brain
LSD, mescaline, psilocybin, and PCP are drugs that cause
hallucinations, which can alter a person's perception of reality. LSD,
mescaline, and psilocybin cause their effects by initially disrupting
the interaction of nerve cells and the neurotransmitter serotonin.
It is distributed throughout the brain and spinal cord, where the
serotonin system is involved with controlling of the behavioral,
perceptual, and regulatory systems. This also includes mood, hunger,
body temperature, sexual behavior, muscle control, and sensory
perception. Certain hallucinogens, such as PCP, act through a glutamate
receptor in the brain which is important for perception of pain,
responses to the environment, and learning and memory.
Thus far, there have been no properly controlled research studies on the
specific effects of these drugs on the human brain, but smaller studies
have shown some of the documented effects associated with the use of
hallucinogens.
Naming and taxonomy
Psychedelic nomenclature
The
class of drugs described in this article has been described by a
profusion of names, most of which are associated with a particular
theory of their nature.
Louis Lewin started out in 1928 by using the word phantastica
as the title of his ground-breaking monograph about plants that, in his
words, "bring about evident cerebral excitation in the form of
hallucinations, illusions and visions [...] followed by unconsciousness
or other symptoms of altered cerebral functioning". But no sooner had
the term been invented, or Lewin complained that the word "does not
cover all that I should wish it to convey", and indeed with the
proliferation of research following the discovery of LSD came numerous
attempts to improve on it, such as hallucinogen, phanerothyme, psychedelic, psychotomimetic, psychogenic, schizophrenogenic, cataleptogenic, mysticomimetic, psychodysleptic, and entheogenic.
The word psychotomimetic, meaning "mimicking psychosis",
reflects the hypothesis of early researchers that the effects of
psychedelic drugs are similar to naturally occurring symptoms of
schizophrenia, though it has since been discovered that some
psychedelics resemble endogenous psychoses better than others. PCP and
ketamine are known to better resemble endogenous psychoses because they
reproduce both positive and negative symptoms of psychoses, while
psilocybin and related hallucinogens typically produce effects
resembling only the positive symptoms of schizophrenia.
While the serotonergic psychedelics (LSD, psilocybin, mescaline, etc.)
do produce subjective effects distinct from NMDA antagonist
dissociatives (PCP, ketamine, dextrorphan), there is obvious overlap in
the mental processes that these drugs affect and research has discovered
that there is overlap in the mechanisms by which both types of
psychedelics mimic psychotic symptoms. One double-blind study examining the differences between DMT and ketamine hypothesized that classically psychedelic drugs most resemble paranoid schizophrenia while dissociative drugs best mimicked catatonic subtypes or otherwise undifferentiated schizophrenia.
The researchers expressed the view that "a heterogeneous disorder like
schizophrenia is unlikely to be modeled accurately by a single
pharmacological agent."
The word psychedelic was coined by Humphrey Osmond and has
the rather mysterious but at least somewhat value-neutral meaning of
"mind manifesting". The word entheogen, on the other hand, which
is often used to describe the religious and ritual use of psychedelic
drugs in anthropological studies, is associated with the idea that it
could be relevant to religion. The words entactogen, empathogen, dissociative and deliriant,
at last, have all been coined to refer to classes of drugs similar to
the classical psychedelics that seemed deserving of a name of their own.
Many different names have been proposed over the years for this drug class. The famous German toxicologist Louis Lewin used the name phantastica earlier in this century, and as we shall see later, such a descriptor is not so farfetched. The most popular names—hallucinogen, psychotomimetic, and psychedelic ("mind manifesting")—have often been used interchangeably. Hallucinogen is now, however, the most common designation in the scientific literature, although it is an inaccurate descriptor of the actual effects of these drugs. In the lay press, the term psychedelic is still the most popular and has held sway for nearly four decades. Most recently, there has been a movement in nonscientific circles to recognize the ability of these substances to provoke mystical experiences and evoke feelings of spiritual significance. Thus, the term entheogen, derived from the Greek word entheos, which means "god within", was introduced by Ruck et al. and has seen increasing use. This term suggests that these substances reveal or allow a connection to the "divine within". Although it seems unlikely that this name will ever be accepted in formal scientific circles, its use has dramatically increased in the popular media and on internet sites. Indeed, in much of the counterculture that uses these substances, entheogen has replaced psychedelic as the name of choice and we may expect to see this trend continue.
Taxonomy
Hallucinogens
can be classified by their subjective effects, mechanisms of action,
and chemical structure. These classifications often correlate to some
extent. In this article, they are classified as psychedelics, dissociatives, and deliriants,
preferably entirely to the exclusion of the inaccurate word
hallucinogen, but the reader is well advised to consider that this
particular classification is not universally accepted. The taxonomy used
here attempts to blend these three approaches in order to provide as
clear and accessible an overview as possible.
Almost all hallucinogens contain nitrogen and are therefore classified as alkaloids. THC and salvinorin A are exceptions. Many hallucinogens have chemical structures similar to those of human neurotransmitters, such as serotonin, and temporarily modify the action of neurotransmitters and/or receptor sites.
Leo Hollister's five criteria for establishing that a drug is hallucinogenic are as follows:
(1) in proportion to other effects, changes in thought, perception, and mood should predominate; (2) intellectual or memory impairment should be minimal; (3) stupor, narcosis, or excessive stimulation should not be an integral effect; (4) autonomic nervous system side effects should be minimal; and (5) addictive craving should be absent.
Lewin's classes
A classical classification, mainly of historical interest, is that of Lewin (Phantastica, 1928):
- Class I Phantastica roughly correspond to the psychedelics, which is a more modern term usually used as synonym to "hallucinogen" by people with positive attitudes towards them. Here the term is used a bit differently to discriminate one particular class of hallucinogens which it seems to describe best. They typically have no sedative effects (sometimes the opposite) and there is usually a clearcut memory to their effects. These drugs have also been referred to as the "classical" hallucinogens.
- Class II Phantastica correspond to the other classes in
our scheme. They tend to sedate in addition to their hallucinogenic
properties and there often is an impaired memory trace after the effects
wear off.
Pharmacological classes of hallucinogens
One
possible way of classifying the hallucinogens is by their chemical
structure and that of the receptors they act on. In this vein, the
following categories are often used:
- Psychedelics
- Serotonergics (5-HT2A receptor agonists or classical psychedelics) such as mescaline from peyote (Lophophora williamsii)
- Indoles / Tryptamines such as psilocybin from "magic" mushrooms (Psilocybe)
- Ergolines such as lysergol from morning glory (Convolvulaceae)
- Lysergamides such as LSD ("acid"), derived from ergot (Claviceps purpurea)
- Beta-carbolines (monoamine oxidase inhibitors or MAOIs, specifically reversible inhibitors of monoamine oxidase A or RIMAs) such as harmala alkaloids such as norharman from ayahuasca (Banisteriopsis caapi)
- Complexly substituted tryptamines such as ibogaine from iboga (Tabernanthe iboga)
- Ergolines such as lysergol from morning glory (Convolvulaceae)
- Phenethylamines such as mescaline
- Empathogen–entactogens such as MDA
- Substituted methylenedioxyphenethylamines (serotonin releasing agents) such as MDMA ("ecstasy")
- Empathogen–entactogens such as MDA
- Indoles / Tryptamines such as psilocybin from "magic" mushrooms (Psilocybe)
- Cannabinoidergics (CB-1 receptor agonists or atypical psychedelics) such as THC from cannabis (Cannabis)
- Serotonergics (5-HT2A receptor agonists or classical psychedelics) such as mescaline from peyote (Lophophora williamsii)
- Dissociatives
- Antiglutamatergics (NMDA receptor antagonists or classical dissociatives) such as "laughing gas" (nitrous oxide) and ketamine
- Opioidergics (sometimes regarded as atypical psychedelics) (κ-Opioid receptor agonists or atypical dissociatives) such as salvinorin A from Salvia divinorum and pentazocine
- Deliriants
- Anticholinergics (muscarinic acetylcholine receptor antagonists or classical deliriants) such as tropane alkaloids such as atropine from deadly nightshade (Atropa belladonna) and diphenhydramine (Benadryl)
- GABAergics (sometimes regarded as atypical dissociatives) (GABAA receptor agonists, and some positive allosteric modulators of the GABAA receptor, or atypical deliriants) such as muscimol from fly agaric (Amanita muscaria) and zolpidem (Ambien)
Problems with structure-based frameworks is that the same structural
motif can include a wide variety of drugs which have substantially
different effects. For example, both methamphetamine and MDMA
are substituted amphetamines, but methamphetamine has a much stronger
stimulant action than MDMA, with none of the latter's empathogenic
effects. Also, drugs commonly act on more than one receptor; DXM,
for instance, is primarily dissociative in high doses, but also acts as
a serotonin reuptake inhibitor, similar to many phenethylamines.
Even so, in many cases structure-based frameworks are still very useful, and the identification of a biologically active pharmacophore and synthesis of analogues of known active substances remains an integral part of modern medicinal chemistry.